Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled [Yahoo! Finance]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Yahoo! Finance
KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed for human pilot study #3 (the "Study") investigating a DehydraTECH-processed version of the dual action glucagon-like peptide-1 ("GLP-1") + glucose-dependent insulinotropic peptide ("GIP") receptor agonist tirzepatide (sold commercially as Zepbound®) in an oral dose format. The Study has been dosed in nine (9) healthy volunteers. The final seven-day dosing phase, wherein all subjects received the opposite treatment condition from that which they received during the initial dosing phase, was completed on November 16 th . The initial dosing phase of either a seven-day regimen of oral DehydraTECH-processed tirzepatide capsules or a single injected tirzepatide dose was reported upon positively several weeks ago. No serious adverse events have been observed t
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria's Registered GLP-1 Study #4 Begins Dosing [Yahoo! Finance]Yahoo! Finance
- Lexaria's Registered GLP-1 Study #4 Begins DosingAccesswire
- Lexaria Forms New Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Lexaria Forms New Scientific Advisory BoardAccesswire
- Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria BioscienceAccesswire
LEXX
Sec Filings
- 12/18/24 - Form 8-K
- 12/18/24 - Form EFFECT
- 12/16/24 - Form POS
- LEXX's page on the SEC website